Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,579 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Pancreatic Cancer, Lymphadenopathy, Cholangiocarcinoma
Interventions: 22G SharkCore™ needle, 22G BNX EUS-FNA Needle; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Actinic Keratoses
Interventions: BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 18F-fluciclovine PET Scan; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 18 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Depression, Psychosis, Anhedonia
Interventions: Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions: bioelectric field imaging, biopsy, histopathologic examination; Procedure
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Hampton, Virginia

Conditions: Nicotine Dependence
Interventions: Nicotine patch, ENDS, Placebo patch, Placebo ENDS; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease
Interventions: Coronary Artery Stenting, Endeavor; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Interventions: Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurofibromatosis 1
Interventions: Kybella, Asclera; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lichen Planus
Interventions: INCB018424; Drug
Lead sponsor: Aaron R. Mangold; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cervical Intraepithelial Neoplasia
Interventions: CervImage device; Device
Lead sponsor: Carilion Clinic; Other
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Post-Treatment Lyme Disease
Interventions: taVNS; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System Lesion
Interventions: GammaTile seed loader; Device
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Herpes
Interventions: Versabase gel with sarracenia purpurea 20% liquid extract, placebo (versabase gel only); Other
Lead sponsor: Naturopaths International; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Chronic Stress, Systemic Inflammation, Mobility and Independence
Interventions: Eutectogel Sensors and Microneedle Patches; Device
Lead sponsor: Tufts University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Inflammation
Interventions: Ibuprofen, Placebo tablet; Drug
Lead sponsor: Martin Angst; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nicotine Dependence
Interventions: Extended treatment; Drug
Lead sponsor: Stanford University; Other
Eligibility: 14 Years to 18 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst
Interventions: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Respiration Rate, Monitoring, Physiologic
Interventions: Chest Worn Respiratory Rate Monitor; Device
Lead sponsor: Perin Health Devices; Industry
Eligibility: 22 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Cocaine Use Disorder
Interventions: lorcaserin, Placebo Oral Tablet, Substance use counseling, ACASI, Cocaine metabolites, Ecological Momentary Assessment (EMA), Balloon Analogue Risk Task (BART), Qualitative Exit Interview; Drug · Behavioral · Diagnostic Test
Lead sponsor: Glenn-Milo Santos; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions: Poly-ICLC; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Carotid Artery Calcification, Carotid Artery Diseases
Interventions: Carotid Intravascular Lithotripsy (IVL); Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more

Conditions: Tobacco Dependence
Interventions: Innovative System, Standard Treatment Control (STC); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions

Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment

The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Topical Ruxolitinib Lichen Planus

A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings

taVNS for Persistent Symptoms From Lyme Disease

Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device

Hsv 1 and 2 Gowey Protocol Versus Placebo

Assessing the Feasibility of Multi-modal Biosensing for Monitoring Mobility and Cognition in Older Adults

Study of Experimental Models of Pain and Inflammation.

Extended Cessation Treatment for Teen Smokers

Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery

Respiratory Rate Validation Study

Treatment With Lorcaserin for Cocaine Use: The TLC Study

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

Tobacco Intervention in Buprenorphine Treatment